(Q73836567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

HER2 and surgery: more questions to answer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

David R Spigel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 August 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

9383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

502-503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

What might a stromal response mean to prostate cancer progression?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

Wound-Induced Tumor Progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914147-5

7 January 2021

10.1016/S0140-6736(03)14147-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932377%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference